SmaBio Labs’ Post

Modern treatments depend heavily on the development of sophisticated sustained-release dosage forms, which offer consistent drug delivery, lower dosage frequency, and enhance patient adherence to treatment plans. For chronic disorders like cardiovascular diseases, where stable plasma medication levels might avoid oscillations that result in negative events, these developments are especially revolutionary. These formulations, which incorporate cutting-edge technologies and creative excipients, not only improve therapeutic results but also tackle issues like reducing side effects and customizing drug release to suit patient requirements and lifestyles.

Multiple Sclerosis Market Assessment 2034 | Multiple Sclerosis Therapies, FDA Approval, Clinical trials, Prevalence, Treatment Algorithms and Companies by DelveInsight | Immune Response BioPharma: Multiple Sclerosis Market As per DelveInsight, the Multiple Sclerosis Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Multiple Sclerosis in the 7MM. DelveInsight’s … Continue reading → #Business #Europe #HealthMedicine #PharmaceuticalsBiotech #US

🚶♀️Patients with Rheumatoid Arthritis (RA) struggle on the daily with chronic inflammation of the joints, along with weakness, fatigue, and unintentional weight loss. 📈 The IDEA-FAST Clinical Observation Study is aiming to monitor up to 200 RA patients through cutting-edge digital wearables and comprehensive questionnaires. We shortly explore the hallmarks of RA and the efforts of IDEA-FAST. Learn more about our project's endeavors at idea-fast.eu Innovative Health Initiative (IHI) EFPIA - European Federation of Pharmaceutical Industries and Associations #neurodegenerativediseases #sleepandfatigue #systemiclupuserythematosus

A recent study by Christopher Willy Schwarz and colleagues presented at #EADV24 reveals insight into 𝐧𝐨𝐧-𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐬𝐰𝐢𝐭𝐜𝐡𝐞𝐬 between adalimumab products in patients with psoriasis. ✅ The risk of discontinuation was 0-8% within six months among 180 patients undergoing non-medical switches. 💉 The highest discontinuation rate was found for patients switching from the reference to a biosimilar drug. 🌍 The results are comparable with previous studies, thus adding to the growing evidence of the safety of adalimumab switches. 📸 Hear more about the exciting results at Dermatologi DK: https://lnkd.in/dcccBnu7

FibroBiologics (Nasdaq: FBLG) has entered a master services agreement with Charles River Laboratories to develop and manufacture cell-based therapies for chronic diseases. Charles River Global Manufacturing corporate senior vice-president Kerstin Dolph stated: “Charles River’s work with FibroBiologics is part of a larger commitment to supporting next-generation regenerative medicine through the adoption of innovative therapies. We are excited to collaborate with FibroBiologics and support the development of a therapy that has the potential to transform patient care for those impacted by diabetic foot wounds.” Click here for the full article - https://lnkd.in/d2X23nan #pharma #drugmanufacturing #chronicdiseases #celltherapy #regenerativemedicine #diabetes

🚀 Continuing Your Pharma Education: A Deep Dive into Atherosclerosis 💓 Our latest article uncovers the complex nature of Atherosclerosis, covering its causes, symptoms, and essential treatments for managing this widespread condition. A must-read for pharmaceutical newcomers! #Atherosclerosis #HeartHealth #PharmaEducation #CardiovascularDisease #MedicalKnowledge #PharmaceuticalIndustry #HealthCare #MedicalRepresentative #PharmaColleagues #Health #MedicalStudent #HealthTipsHub Read the full article now! 👇 https://lnkd.in/dApzPD4R

Bristol Myers Squibb Presents the Long-Term P-III (MAVA-LTE) Trial Data of Camzyos to Treat Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) #bms #camzyos #symptomaticobstructivehypertrophiccardiomyopathy #clinicaltrial #phase3 #mavalte

🌟 Exciting Breakthrough in MPS II Treatment! 🌟 We’re thrilled to announce the publication of groundbreaking research: “Analysis of caregiver perspectives on patients with mucopolysaccharidosis II treated with pabinafusp alfa.” This study marks the first exploration into caregiver experiences with the revolutionary blood-brain barrier (BBB) penetrating intravenous enzyme replacement therapy, exclusively available in Japan through JCR Pharmaceuticals Ltd. 🔍 Why This Matters: For the first time, we’re hearing directly from caregivers about the transformative impact of pabinafusp alfa (Izcargo) on the lives of those living with MPS II. These insights are not just a step forward in understanding the comprehensive benefits of innovative treatments but also a leap towards enhancing patient care. 🌏 A Global First: Exclusive to Japan, pabinafusp alfa represents a pioneering approach in addressing the neurological symptoms of MPS II patients, offering hope and opening doors to potential future advancements worldwide. 💡 The Power of Collaboration: This research signifies the strength of collaboration between caregivers, patients, and the medical community. Together, we’re making strides in tackling rare diseases and improving quality of life. 📚 Dive into the Full Article: [https://lnkd.in/gdAt2Ffb] Let’s spread the word about this remarkable innovation and celebrate the incredible journey of caregivers, patients, and JCR Pharmaceuticals Ltd. in redefining treatment possibilities! #MPSII #RareDiseases #InnovativeTreatment #JCRPharmaceuticals #PatientCare #ScientificBreakthrough

💥SUN PHARMA and #Moebius Medical announced promising results from a clinical trial of their new treatment for knee osteoarthritis, MM-II.💥 Here are the key points: 🔺️ Significant Pain Reduction: Patients receiving a single intra-articular injection of MM-II experienced a 50% greater reduction in knee osteoarthritis pain compared to those who received a placebo. 🔺️Reduced Rescue Medication Usage: Those treated with MM-II also required less additional medication to manage their pain. 🔺️Durable Pain Relief: The pain relief from MM-II lasted up to 26 weeks post-injection. 🔺️Safety Profile: MM-II was found to be as safe as the placebo, with no significant adverse effects reported. 🔺️Next Steps: Sun Pharma and Moebius Medical plan to proceed with a Phase 3 clinical program and seek regulatory approvals in the European Union. These findings highlight MM-II's potential as an effective and long-lasting treatment option for knee osteoarthritis pain. #sunpharma #moebiusmedical #osteoporosis #MM #regulatory #approval #europeanunion #painrelief #eular

Challenges In Diagnosing Dementia And Alzheimer’s In Diabetic Patients Some medicines used to treat diabetes or its complications can affect cognitive function, making it challenging to discern whether a patient's cognitive symptoms are due to the disease itself, the medications, or an emerging neurodegenerative condition. VERIFIED By: Dr Aravind Badiger, Technical Director, BDR Pharmaceuticals Written by  Tavishi Dogra  |Updated : October 14, 2024 12:44 PM IST The relationship between diabetes and cognitive decline, particularly in the form of dementia and Alzheimer's disease, has garnered increasing attention in recent years. With both diabetes and Alzheimer's on the rise globally, diagnosing these neurodegenerative conditions in diabetic patients presents significant challenges for healthcare professionals. #Pharmaceuticals #pharma #Alzhimers